Bluebird bio reaffirms Carlyle deal as Ayrmid misses deadline
Rival bidder Ayrmid has failed to deliver a binding, fully financed proposal by the agreed date.
Cytiva-Cell & Gene Therapy WP 2
Verve’s shares jump by more than 26% on Lilly-partnered gene therapy data
MeiraGTx seeks UK approval after gene therapy restores sight in children born blind
A2 Biotherapeutics raises $80m to advance CAR-T therapies for solid tumours
GEMMABio raises $34m to advance gene therapy programmes
Takeda and Alloy Therapeutics partner to make off-the-shelf CAR-T therapies
Intellia’s gene editing therapy shows early potential in rare heart condition
bit.bio defends European patent for ‘novel’ opti-ox technology
